Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Adrenal Myelolipoma

In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Adrenal Myelolipoma

Maria R. Bokhari et al.
Free Books & Documents

Excerpt

Adrenal myelolipomas are benign, nonfunctional adrenal neoplasms predominantly composed of mature adipose tissue and intermixed myeloid tissue. They comprise 6% to 16% of all adrenal incidentalomas and are the second most common cause of adrenal lesions after adrenal adenomas.

The increased prevalence of adrenal myelolipomas is primarily due to markedly increased detection because of the wider accessibility and usage of computed tomography (CT) and magnetic resonance imaging (MRI) scans for unrelated reasons. The pathogenesis of adrenal myelolipoma is believed to either be due to metaplastic change in the mesenchymal cells or to overstimulation by adrenocorticotrophic hormone (ACTH).

Clinically, they are usually small and asymptomatic but may present with abdominal pain, nausea, or vomiting. On CT scan, they appear as well-circumscribed, hypodense masses with an attenuation of 90 to 120 Hounsfield units (HU) or lower, depending on their fat content.

Myelolipomas are rarely encountered outside the adrenal glands and are termed extra-adrenal myelolipomas, most often found in the retroperitoneum, thorax, or pelvis. Surgical resection is indicated in cases of significant adrenal neoplasm growth (>1 cm in defined time period), size >7cm due to chance of rupture and bleeding, symptomatic pain or mass effect, suspicion of malignancy, or hormonal hypersecretion.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Maria Bokhari declares no relevant financial relationships with ineligible companies.

Disclosure: Hassam Zulfiqar declares no relevant financial relationships with ineligible companies.

Disclosure: Stephen Leslie declares no relevant financial relationships with ineligible companies.

Disclosure: Vishnu Garla declares no relevant financial relationships with ineligible companies.

References

    1. Decmann Á, Perge P, Tóth M, Igaz P. Adrenal myelolipoma: a comprehensive review. Endocrine. 2018 Jan;59(1):7-15. - PubMed
    1. Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T. CT and MRI of adrenal gland pathologies. Quant Imaging Med Surg. 2018 Sep;8(8):853-875. - PMC - PubMed
    1. Haro A, Fujishita T, Nishikawa H, Taguchi Y, Kouda T, Kajiwara K, Makino H, Kanematsu T, Oshiro Y, Yokoyama H. A rare case of gradual enlargement of a multifocal myelolipoma of the posterior mediastinum for 12 years after surgical resection of an adrenal myelolipoma. Int J Surg Case Rep. 2018;51:400-403. - PMC - PubMed
    1. Wadood DQ, Qureshi DSA, Singh DP, Freedman DJ. A rare case of co-existing adrenal and pelvic myelolipomas. Radiol Case Rep. 2018 Oct;13(5):999-1002. - PMC - PubMed
    1. Steka X, Martens F, Renzulli MM, Hauswirth F, Vrugt B, Renzulli P. Adrenal myelolipoma: Defining the role of surgery. A case report. Int J Surg Case Rep. 2022 Sep;98:107527. - PMC - PubMed

Publication types

LinkOut - more resources